Pregabalin Alternatives Compared
| Pregabalin | Topiramate | Aimovig (erenumab) |
|
|---|
| Pregabalin | Topiramate | Aimovig (erenumab) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Pregabalin is used in the treatment of nerve pain and also to prevent seizures. Drowsiness or dizziness are common side effects, and it has the potential to be misused. Prescribed for Neuropathic... View more |
Prescription only
Topiramate may be prescribed either alone or in combination with other medications for the treatment of certain types of epilepsy, or it may be given for the prevention of migraines. Drowsiness is a... View more |
Prescription only
Aimovig is used to prevent migraines in adults and is self-administered as a subcutaneous injection once a month. Injection site reactions (pain, redness, or swelling) and constipation are the most... View more |
Related suggestions Migraine Prevention (Migraine Prophylaxis)
|
|||||||||||||||||||||||
| More about Pregabalin | More about Topiramate | More about Aimovig (erenumab) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Pregabalin has an average rating of 6.8 out of 10 from a total of 1688 ratings on Drugs.com. 58% of reviewers reported a positive effect, while 23% reported a negative effect. |
Topiramate has an average rating of 6.3 out of 10 from a total of 1347 ratings on Drugs.com. 50% of reviewers reported a positive effect, while 27% reported a negative effect. |
Aimovig has an average rating of 5.2 out of 10 from a total of 655 ratings on Drugs.com. 38% of reviewers reported a positive effect, while 43% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
View all Pregabalin side effects |
View all Topiramate side effects |
View all Aimovig side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
Lower cost generic |
Lower cost generic |
N/A |
||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Pregabalin prices |
View all Topiramate prices |
View all Aimovig prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Lyrica, Lyrica CR | Eprontia, Qudexy XR, Topamax, Trokendi XR |
N/A |
||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
6.3 hours |
56 hours |
672 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Some potential for abuse
Has a low potential for abuse relative to those in schedule 4. Has a currently accepted medical use in treatment in the United States. Abuse may lead to limited physical dependence or psychological dependence relative to those in schedule 4. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 287 drugs are known to interact with Pregabalin:
|
A total of 291 drugs are known to interact with Topiramate:
|
A total of 3 drugs are known to interact with Aimovig:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
N/A |
December 24, 1996 |
May 17, 2018 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.